A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy
Introduction Treatment‐emergent small cell/neuroendocrine prostate cancer occurs predominantly in advanced or metastatic castration‐resistant prostate cancer that arises when prostate adenocarcinoma is transformed after androgen deprivation therapy. The clinical course for the pathogenesis involved...
Main Authors: | Taku Naiki, Aya Naiki‐Ito, Tatsuya Kawai, Hirokazu Komatsu, Ryutaro Nishikawa, Masakazu Gonda, Maria Aoki, Yosuke Sugiyama, Yoshihiko Tasaki, Takahiro Yasui |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-11-01
|
Series: | IJU Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/iju5.12501 |
Similar Items
-
Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
by: Riko Ikeda, et al.
Published: (2024-03-01) -
A rare case of long‐term survival from metachronous bilateral adrenal metastasis of lung adenocarcinoma after combined surgical removal and immunochemotherapy
by: Nami Tomiyama, et al.
Published: (2022-11-01) -
Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
by: Yoshiyuki Miyazawa, et al.
Published: (2023-01-01) -
BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
by: Keisuke Okubo, et al.
Published: (2023-08-01) -
Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
by: Tatsuaki Daimon, et al.
Published: (2021-07-01)